On Tuesday, December 5th, Kristina Brooks, PharmD, of the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences presented on: “Drug-Drug Interactions Seen in Treatment for Hepatitis C”
1. Discuss recent developments in the treatment of HCV infection, including protease inhibitors and other emerging therapies.
2. Recall clinically important adverse effects, contraindications, and drug-drug interactions associated with medications used in the treatment of HCV infection.
3. Devise strategies for managing drug interactions with HCV therapies.
Kristina Brooks, PharmD, is a postdoctoral fellow at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, and is currently under the mentorship of Dr. Jennifer Kiser and Dr. Peter Anderson. Dr. Brooks received her PharmD from the University of Michigan, and completed a two-year fellowship in clinical pharmacokinetics at the National Institutes of Health Clinical Center prior to transitioning to the University of Colorado. Dr. Brooks’s research interests include antiviral pharmacology and drug-drug interactions in individuals living with HIV and viral hepatitis.